In Search of the Mechanism of APOL1 Kidney Disease.
作者信息
Friedman David J, Pollak Martin R
机构信息
Division of Nephrology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; and Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
出版信息
J Am Soc Nephrol. 2024 Jun 1;35(6):815-817. doi: 10.1681/ASN.0000000000000368. Epub 2024 Apr 10.
Abstract
摘要
相似文献
1
In Search of the Mechanism of APOL1 Kidney Disease.探寻载脂蛋白L1肾病的发病机制
J Am Soc Nephrol. 2024 Jun 1;35(6):815-817. doi: 10.1681/ASN.0000000000000368. Epub 2024 Apr 10.
2
Apolipoprotein L1 and Kidney Disease in African Americans.载脂蛋白L1与非裔美国人的肾脏疾病
Trends Endocrinol Metab. 2016 Apr;27(4):204-215. doi: 10.1016/j.tem.2016.02.002. Epub 2016 Mar 3.
3
Arrest of the true culprit and acquittal of the innocent? Genetic revelations charge APOL1 variants with kidney disease susceptibility.逮捕真凶并宣告无辜者无罪？基因揭示表明APOL1变异体与肾脏疾病易感性有关。
Int Urol Nephrol. 2010 Dec;42(4):1131-4. doi: 10.1007/s11255-010-9863-z. Epub 2010 Nov 16.
4
APOL1 Kidney Disease Risk Variants: An Evolving Landscape.载脂蛋白L1肾病风险变异体：不断演变的格局
Semin Nephrol. 2015 May;35(3):222-36. doi: 10.1016/j.semnephrol.2015.04.008.
5
Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans.载脂蛋白 L1 肾病风险变异与非裔美国人高密度脂蛋白亚组分浓度相关。
Nephrol Dial Transplant. 2011 Nov;26(11):3805-10. doi: 10.1093/ndt/gfr542. Epub 2011 Sep 19.
6
APOL1 nephropathy: from gene to mechanisms of kidney injury.载脂蛋白L1肾病：从基因到肾损伤机制
Nephrol Dial Transplant. 2016 Mar;31(3):349-58. doi: 10.1093/ndt/gfu391. Epub 2015 Jan 5.
7
The biology of APOL1 with insights into the association between APOL1 variants and chronic kidney disease.APOL1 的生物学特性及其与 APOL1 变异体和慢性肾病之间关联的研究进展。
Clin Exp Nephrol. 2014 Apr;18(2):238-42. doi: 10.1007/s10157-013-0907-4.
8
APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.APOL1肾病风险变异与非裔美国人高密度脂蛋白谱改变有关。
Nephrol Dial Transplant. 2016 Apr;31(4):602-8. doi: 10.1093/ndt/gfv229. Epub 2015 Jul 6.
9
Genetics: APOL1 risk variants drive kidney disease in mice.
Nat Rev Nephrol. 2017 May;13(5):259. doi: 10.1038/nrneph.2017.35. Epub 2017 Mar 6.
10
APOL1 and kidney disease: new insights leading to novel therapies.载脂蛋白L1与肾脏疾病：通向新疗法的新见解
Am J Kidney Dis. 2015 Jul;66(1):9-11. doi: 10.1053/j.ajkd.2015.05.005.
引用本文的文献
1
Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities.靶向肾小球肾病中的I型干扰素通路：原理与治疗机会
Kidney Int Rep. 2024 Oct 21;10(1):29-39. doi: 10.1016/j.ekir.2024.10.013. eCollection 2025 Jan.
本文引用的文献
1
Genotyping Is Incomplete without Testing for the Protective M1 Modifier p.N264K Variant.若不检测保护性M1修饰因子p.N264K变体，则基因分型不完整。
Glomerular Dis. 2024 Feb 20;4(1):43-48. doi: 10.1159/000537948. eCollection 2024 Jan-Dec.
2
APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease.APOL1 介导的单价阳离子转运有助于 APOL1 介导的肾脏病中的足细胞病变。
J Clin Invest. 2024 Jan 16;134(5):e172262. doi: 10.1172/JCI172262.
3
Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. Reply.依那沙普林用于携带两种载脂蛋白L1变体的人群的蛋白尿性肾病。回复。
N Engl J Med. 2023 Jun 29;388(26):2491. doi: 10.1056/NEJMc2304780.
4
Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytes.载脂蛋白 L1 (APOL1) 在 HEK-293 细胞和人足细胞中的阳离子电流。
Pflugers Arch. 2023 Mar;475(3):323-341. doi: 10.1007/s00424-022-02767-8. Epub 2022 Nov 30.
5
Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease.APOL1BAC 转基因小鼠模型中的隐性、功能获得毒性类似于人类的 APOL1 肾脏疾病。
Dis Model Mech. 2021 Aug 1;14(8). doi: 10.1242/dmm.048952. Epub 2021 Aug 5.
6
Coiled-coil binding of the leucine zipper domains of APOL1 is necessary for the open cation channel conformation.卷曲螺旋结合的载脂蛋白 L1 的亮氨酸拉链域是阳离子通道开放构象所必需的。
J Biol Chem. 2021 Sep;297(3):101009. doi: 10.1016/j.jbc.2021.101009. Epub 2021 Jul 29.
7
Kidney-disease-associated variants of Apolipoprotein L1 show gain of function in cation channel activity.载脂蛋白 L1 的与肾脏疾病相关变体显示在阳离子通道活性方面具有功能获得。
J Biol Chem. 2021 Jan-Jun;296:100238. doi: 10.1074/jbc.RA120.013943. Epub 2021 Jan 9.
8
Cation channel conductance and pH gating of the innate immunity factor APOL1 are governed by pore-lining residues within the C-terminal domain.先天免疫因子 APOL1 的阳离子通道电导和 pH 门控由 C 末端结构域内的孔衬残基控制。
J Biol Chem. 2020 Sep 18;295(38):13138-13149. doi: 10.1074/jbc.RA120.014201. Epub 2020 Jul 29.
9
APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.APOL1肾病风险变异体通过消耗细胞内钾离子和诱导应激激活蛋白激酶而导致细胞毒性。
Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):830-7. doi: 10.1073/pnas.1522913113. Epub 2015 Dec 23.
10
APOL1 toxin, innate immunity, and kidney injury.载脂蛋白L1毒素、固有免疫与肾损伤。
Kidney Int. 2015 Jul;88(1):28-34. doi: 10.1038/ki.2015.109. Epub 2015 Apr 8.
Zotero 插件